NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









PhAST Diagnostics

PhAST Diagnostics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://phast.ai/

Last Round

Series B

May 8, 2025

Total Funding Raised

$18.57M

Company Overview

PhAST Diagnostics is a healthcare technology company that develops an AI-powered, cloud-based platform for rapid infectious disease diagnostics to combat antibiotic resistance.

Sector

Healthcare & Life Sciences

Verticals

Medical AI, Medical Imaging, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Hardware + Subscription, Hardware Sales, Usage-Based SaaS, Government Contracts

AI Layer

Application

Keywords

antimicrobial susceptibility testingASTrapid ASTantibiotic resistancesingle-cell imagingdiagnostic platforminfectious disease diagnosticsAI computer visionsuperbug diagnosticsphenotypic testingantimicrobial stewardshippathogen identificationclinical decision supporthardware + subscription

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PhAST Diagnostics Comparables

Compare PhAST Diagnostics with similar companies based on industry and business-model similarity.

PhAST Diagnostics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Resistell AG
88%
Pattern Bioscience
87%
SeLux Diagnostics
86%

PhAST Diagnostics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 8, 2025
Series AJan 18, 2022
GrantSep 3, 2019
GrantAug 1, 2019

Key People

Founding team and executive leadership

Roman Stocker

Co-founder And Chief Scientific Officer

Founding Team

Kwangmin Son

CEO

Executive Team

PhAST Diagnostics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 8, 2025

    $3.47M round raised

  • Apr 14, 2024

    Grew 17% QoQ, from 24 to 28 employees.

PhAST Diagnostics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PhAST Diagnostics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PhAST Diagnostics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range27
Year Founded2016
Last FundingMay 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.